Circulation. Cardiovascular interventions
Authors: Butala NM, Patel NK, Chhatwal J, Vahdat V, Pomerantsev EV, Albaghdadi M, Sakhuja R, Rosenzweig A, Elmariah S
Cureus
Authors: Bayanzay K, Razzeto A, Amoozgar B, Garala P, Holman A
European journal of medical research
Authors: Meo SA, Abukhalaf AA, Alomar AA, AlMutairi FJ, Usmani AM, Klonoff DC
Medical Science Educator
Authors: Ransohoff A, Boscardin C, Hauer KE, Wlodarczyk S
Journal of the American Geriatrics Society
Authors: Sharma S, Katz R, Dubin RF, Drew DA, Gutierrez OM, Shlipak MG, Sarnak MJ, Ix JH
Journal of the American Geriatrics Society
Authors: Dzeng E, Morrison RS
Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry
Authors: Zakaras JM, Sarkar U, Bibbins-Domingo K, Mangurian CV
AIDS care
Authors: Marson K, Ndyabakira A, Kwarisiima D, Camlin CS, Kamya MR, Havlir D, Thirumurthy H, Chamie G
Volume 71 of Issue 2 | CA: a cancer journal for clinicians
Authors: Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR
The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma ctDNA technologies in both commercial and academic laboratories are in routine or emerging use. The increasing integration of such testing to inform treatment decision making by oncology clinicians has complexities and challenges but holds significant potential to substantially improve patient outcomes. In this review, the authors discuss the current role of plasma ctDNA assays in oncology care and provide an overview of ongoing research that may inform real-world clinical applications in the near future.
View on PubMed
Authors: Stage TB, Hu S, Sparreboom A, Kroetz DL
